Can Prozac cause hair loss? It is a question many people prescribed fluoxetine understandably ask. Fluoxetine — dispensed generically on the NHS and belonging to the selective serotonin reuptake inhibitor (SSRI) class — is one of the UK's most commonly prescribed antidepressants for depression, OCD, and bulimia nervosa. Hair loss (alopecia) is listed as a recognised, albeit uncommon, adverse effect in fluoxetine's UK Summary of Product Characteristics. Understanding how frequently it occurs, why it happens, and what steps to take can help patients make informed decisions alongside their GP or prescribing clinician.

Does Fluoxetine (Prozac) Cause Hair Loss?

Yes — alopecia is a recognised adverse effect listed in fluoxetine's UK SmPC, most commonly presenting as telogen effluvium, a temporary diffuse shedding rather than permanent hair loss.

Experiencing these side effects? Our pharmacists can help you navigate them →

Fluoxetine — commonly known by the brand name Prozac, though usually prescribed generically on the NHS — is one of the most widely used antidepressants in the UK. It belongs to a class of medicines known as selective serotonin reuptake inhibitors (SSRIs), which work by increasing the availability of serotonin in the brain, a neurotransmitter associated with mood regulation, sleep, and emotional wellbeing. Fluoxetine is licensed in the UK for the treatment of depression, obsessive-compulsive disorder (OCD), and bulimia nervosa, as confirmed in its UK Summary of Product Characteristics (SmPC), available via the MHRA's electronic Medicines Compendium (eMC).

Hair loss — medically termed alopecia — is listed as a recognised adverse effect of fluoxetine in its UK SmPC. The specific pattern most commonly associated with SSRIs is telogen effluvium, a temporary, diffuse shedding of hair rather than patchy or permanent baldness. This occurs when hair follicles are prematurely pushed into the resting (telogen) phase of the hair growth cycle.

Whilst the association between fluoxetine and hair loss is documented in the SmPC and supported by post-marketing reports, it is not experienced by the majority of people who take the medication. It is also important to recognise that depression itself can contribute to hair shedding — through physiological stress, poor nutrition, and disrupted sleep — which can make it difficult to determine whether the medication or the underlying condition is the primary cause. Patients should not stop taking fluoxetine without first speaking to their GP or prescribing clinician, as abrupt discontinuation carries its own risks, including discontinuation symptoms.

How Common Is Hair Loss With Fluoxetine?

Hair loss is classified as 'uncommon' in the fluoxetine UK SmPC, affecting an estimated 1 in 100 to 1 in 1,000 users, with onset typically two to four months after starting treatment.

Not sure if this is normal? Chat with one of our pharmacists →

According to the fluoxetine UK SmPC (eMC), hair loss is classified as an uncommon adverse effect, meaning it is estimated to affect between 1 in 100 and 1 in 1,000 people taking the medication. It is worth noting that frequency classifications can vary between different licensed fluoxetine products; patients and clinicians should refer to the SmPC for the specific product dispensed. This places alopecia in a relatively low-frequency category compared to more commonly reported side effects such as nausea, headache, insomnia, and sexual dysfunction.

Post-marketing surveillance data — which captures real-world reports submitted to the MHRA via the Yellow Card scheme — has recorded cases of alopecia associated with fluoxetine use. It is important to understand that spontaneous reporting through Yellow Card is valuable for detecting safety signals, but cannot be used to calculate the precise incidence of a side effect or to confirm direct causation. Factors such as concurrent medications, nutritional deficiencies (particularly iron and ferritin), thyroid dysfunction, and psychological stress can all independently cause or worsen hair loss.

The onset of hair shedding, when it does occur, typically begins two to four months after starting fluoxetine. This reflects the natural delay in the hair growth cycle: in telogen effluvium, there is a lag between the triggering event and visible hair loss, as affected hairs must complete their resting phase before falling out. In most documented cases, the hair loss is reversible, with regrowth typically occurring after dose adjustment or discontinuation of the drug, though any changes should always be managed under medical supervision. Patients who notice significant or distressing hair shedding are encouraged to report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Why Antidepressants May Affect Hair Growth

SSRIs may disrupt hair follicle cycling via serotonin receptors present in follicles, though the exact mechanism is unconfirmed; overlapping factors such as nutritional deficiency and stress also contribute.

The precise mechanism by which SSRIs such as fluoxetine may trigger hair loss is not yet fully established, and the following explanations represent current hypotheses rather than confirmed pathways. Serotonin receptors are present in hair follicles, and it has been proposed that altering serotonergic signalling — as SSRIs do — may interfere with the normal regulation of the hair growth cycle. Specifically, changes in serotonin activity could theoretically influence the transition between the anagen (growth), catagen (transition), and telogen (resting) phases of follicular cycling, though robust clinical evidence for this mechanism in humans remains limited.

Another proposed explanation relates to the physiological stress response. Beginning a new medication, adjusting to its effects, or experiencing side effects can itself act as a systemic stressor, potentially triggering telogen effluvium independently of the drug's direct pharmacological action.

It is also worth considering several overlapping factors that may contribute to hair loss in people taking antidepressants:

• Nutritional factors: SSRI-related appetite changes or nausea may reduce dietary intake of hair-supporting nutrients. Iron deficiency and low ferritin are well-established and common contributors to diffuse hair loss and should be considered in any assessment.

• Thyroid dysfunction: Thyroid disorders are a well-established cause of diffuse hair loss. Certain medications — most notably lithium — are known to affect thyroid function; evidence for a direct thyroid effect from SSRIs specifically is less clear, and any concern should be investigated with appropriate blood tests rather than assumed.

• Polypharmacy: The use of multiple medications simultaneously may increase the overall risk of hair loss, particularly if other prescribed drugs also carry this adverse effect.

Understanding these overlapping factors is essential when assessing a patient who presents with hair loss whilst taking fluoxetine, as a thorough clinical investigation is needed before attributing the cause solely to the antidepressant.

What to Do If You Notice Hair Loss on Fluoxetine

Speak to your GP before changing your medication; first-line investigations include FBC, serum ferritin, and TSH to exclude other causes, with referral to a dermatologist if hair loss is severe or accompanied by red flag features.

If you notice increased hair shedding or thinning whilst taking fluoxetine, the first and most important step is to speak to your GP or prescribing clinician before making any changes to your medication. Stopping fluoxetine abruptly can lead to discontinuation symptoms — including dizziness, irritability, sensory disturbances, and low mood — and should always be done gradually under medical guidance.

Your GP will likely wish to rule out other common causes of hair loss before attributing it to fluoxetine. In line with UK primary care practice (NICE CKS: Alopecia), a focused first-line assessment typically includes:

• Blood tests: full blood count (FBC), serum ferritin, and thyroid-stimulating hormone (TSH) are the standard first-line investigations for diffuse hair loss. Further tests — such as vitamin B12, folate, vitamin D, or zinc — are reserved for cases where there is a specific clinical indication, rather than being ordered routinely.

• A review of your full medication list to identify any other drugs that may contribute to alopecia.

• Assessment of nutritional status, stress levels, and any recent significant life events or illnesses.

Red flags requiring prompt medical attention or dermatology referral include: signs of scarring alopecia (scalp redness, scaling, pustules, pain, or tenderness at the hairline); rapid or patchy hair loss; nail changes; focal scalp scaling that may suggest tinea capitis (a fungal infection); or features of hyperandrogenism in women (such as acne or irregular periods). Scarring alopecias in particular require prompt specialist assessment, as early treatment may prevent permanent hair loss.

If investigations are normal and fluoxetine is considered the likely cause, your clinician may discuss options such as a dose reduction or a switch to an alternative antidepressant, carefully weighing the benefits of your current treatment against the impact of the side effect on your quality of life. NICE NG222 (Depression in Adults, 2022) emphasises shared decision-making, meaning your preferences and concerns should be central to any treatment adjustment.

In the meantime, general hair care advice — such as avoiding excessive heat styling, using gentle shampoos, and ensuring adequate protein intake — may help to minimise further shedding. A referral to a dermatologist is appropriate if hair loss is severe, persistent, or accompanied by any of the red flag features described above.

Alternative Antidepressants and Hair Loss Risk

Hair loss has been reported across multiple antidepressant classes — including other SSRIs, SNRIs, and mirtazapine — and no single agent is definitively proven to carry the lowest risk; switching should be clinician-led.

Hair loss is not unique to fluoxetine — it has been reported, to varying degrees, across multiple antidepressant classes. Within the SSRI family, sertraline, citalopram, escitalopram, and paroxetine have all been associated with alopecia in post-marketing reports, as reflected in their respective UK SmPCs (available via the MHRA eMC) and the BNF. There is currently no robust head-to-head clinical trial data definitively establishing which SSRI carries the lowest hair loss risk, and individual responses vary considerably.

Beyond SSRIs, other antidepressant classes also carry some risk:

• SNRIs (serotonin-noradrenaline reuptake inhibitors) such as venlafaxine and duloxetine have similarly listed alopecia as an adverse effect in their UK SmPCs.

• Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), is sometimes considered when SSRIs are not tolerated, though hair loss has also been reported with its use.

• Tricyclic antidepressants (TCAs) such as amitriptyline are less commonly used as first-line treatments due to their side effect profile, but alopecia has been documented with these agents too.

• Bupropion is licensed in the UK only for smoking cessation (as Zyban) and is not licensed for the treatment of depression; it is not routinely used for this purpose within the NHS and is therefore not a standard alternative to consider in this context.

If switching antidepressants is being considered due to hair loss, this decision should be made collaboratively with a clinician, taking into account the severity of the depressive illness, previous treatment responses, and the full side effect profile of any proposed alternative. Any switch should follow a prescriber-led plan; guidance on safe switching, cross-tapering, and washout periods is available from the Specialist Pharmacy Service (SPS). It is also worth noting that hair loss may resolve spontaneously over time even without changing medication, as the body can adapt to the drug. Patience, monitoring, and open communication with your healthcare team remain the most important tools in managing this side effect effectively.

Frequently Asked Questions